Therapeutic and Prophylactic Effects of Fulvic Acid on a Breast Cancer Model Established by MCF-7 Cell Line in SCID Mice

IF 1.8 4区 医学 Q3 HEALTH CARE SCIENCES & SERVICES
Osman Bilgin Gulcicek, Duygu Sultan Oran, Arzu Temizyurek, Erkan Yavuz, Hakan Yigitbas, Candas Ercetin, Ali Solmaz, Funda Yildirim, Kivilcim Sonmez, Atilla Celik
{"title":"Therapeutic and Prophylactic Effects of Fulvic Acid on a Breast Cancer Model Established by MCF-7 Cell Line in SCID Mice","authors":"Osman Bilgin Gulcicek,&nbsp;Duygu Sultan Oran,&nbsp;Arzu Temizyurek,&nbsp;Erkan Yavuz,&nbsp;Hakan Yigitbas,&nbsp;Candas Ercetin,&nbsp;Ali Solmaz,&nbsp;Funda Yildirim,&nbsp;Kivilcim Sonmez,&nbsp;Atilla Celik","doi":"10.1155/2024/5871444","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Introduction</i>. There is still minimal scientific understanding of effects of fulvic acid (FA) on breast cancer. We investigated the prophylactic, therapeutic, and combined effects of FA in a breast cancer model created using MCF-7 cell line in severe combined immunodeficiency disease (SCID) mice. <i>Results</i>. Four experimental groups were established as the control group (Group C), prophylaxis group (Group P), therapeutic group (Group T), and prophylaxis + therapeutic group (Group P + T). Tumor growth was observed by the in vivo imaging system and macroscopically in mammary glands of all mice (100%) of Group C, microscopically in only one mouse of Group P (12.5%), in four mice in Group T (50%), but only one animal (12.5%) in Group P + T. Immunohistochemistry (IHC) showed that p53 staining was significantly higher in tissues of Group C compared to other groups (<i>P</i> &lt; 0.05). No difference was found in IHC scores for p53 between Group P and P + T (<i>P</i> &gt; 0.05). Bcl-2 staining was significantly higher in Group C compared to Group P + T (<i>P</i> = 0.015) and higher in Group P + T compared to Group T (<i>P</i> = 0.021) but no significant difference was found between Group P and others (<i>P</i> &gt; 0.05). Bax staining was significantly higher in Group C compared to others (<i>P</i> &lt; 0.05) but no significant difference was found between FA groups (<i>P</i> &gt; 0.05). <i>Conclusion</i>. Prophylactic FA treatment can prevent tumor formation by inducing variations in the expression of p53, BcL-2, and Bax proteins in mammary glands of SCID mice before tumor formation. This suggests that FA may be a powerful inhibitory candidate for the prevention of tumorigenesis in breast cancer.</p>\n </div>","PeriodicalId":11953,"journal":{"name":"European Journal of Cancer Care","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5871444","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer Care","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/5871444","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. There is still minimal scientific understanding of effects of fulvic acid (FA) on breast cancer. We investigated the prophylactic, therapeutic, and combined effects of FA in a breast cancer model created using MCF-7 cell line in severe combined immunodeficiency disease (SCID) mice. Results. Four experimental groups were established as the control group (Group C), prophylaxis group (Group P), therapeutic group (Group T), and prophylaxis + therapeutic group (Group P + T). Tumor growth was observed by the in vivo imaging system and macroscopically in mammary glands of all mice (100%) of Group C, microscopically in only one mouse of Group P (12.5%), in four mice in Group T (50%), but only one animal (12.5%) in Group P + T. Immunohistochemistry (IHC) showed that p53 staining was significantly higher in tissues of Group C compared to other groups (P < 0.05). No difference was found in IHC scores for p53 between Group P and P + T (P > 0.05). Bcl-2 staining was significantly higher in Group C compared to Group P + T (P = 0.015) and higher in Group P + T compared to Group T (P = 0.021) but no significant difference was found between Group P and others (P > 0.05). Bax staining was significantly higher in Group C compared to others (P < 0.05) but no significant difference was found between FA groups (P > 0.05). Conclusion. Prophylactic FA treatment can prevent tumor formation by inducing variations in the expression of p53, BcL-2, and Bax proteins in mammary glands of SCID mice before tumor formation. This suggests that FA may be a powerful inhibitory candidate for the prevention of tumorigenesis in breast cancer.

Abstract Image

富马酸对 SCID 小鼠 MCF-7 细胞系建立的乳腺癌模型的治疗和预防作用
导言。科学界对富勒酸(FA)对乳腺癌的影响还知之甚少。我们利用 MCF-7 细胞系在重症联合免疫缺陷病(SCID)小鼠体内建立的乳腺癌模型,研究了富勒酸的预防、治疗和综合作用。研究结果四个实验组分别为对照组(C 组)、预防组(P 组)、治疗组(T 组)和预防 + 治疗组(P + T 组)。通过体内成像系统和宏观观察,C 组所有小鼠(100%)的乳腺中都发现了肿瘤生长,而 P 组仅有一只小鼠(12.5%)、T 组有四只小鼠(50%)和 P + T 组仅有一只动物(12.5%)在显微镜下发现了肿瘤生长。免疫组化(IHC)显示,与其他组相比,C 组组织中的 p53 染色率明显更高(P < 0.05)。P 组和 P + T 组之间的 p53 免疫组化得分没有差异(P > 0.05)。与 P + T 组相比,C 组的 Bcl-2 染色明显更高(P = 0.015),与 T 组相比,P + T 组的 Bcl-2 染色更高(P = 0.021),但 P 组与其他组之间没有发现明显差异(P >;0.05)。与其他组相比,C 组的 Bax 染色明显更高(P < 0.05),但 FA 组之间无明显差异(P > 0.05)。结论预防性 FA 治疗可在肿瘤形成前通过诱导 SCID 小鼠乳腺中 p53、BcL-2 和 Bax 蛋白的表达变化来预防肿瘤的形成。这表明,FA 可能是预防乳腺癌肿瘤发生的一种强有力的抑制候选物质。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Journal of Cancer Care
European Journal of Cancer Care 医学-康复医学
CiteScore
4.00
自引率
4.80%
发文量
213
审稿时长
3 months
期刊介绍: The European Journal of Cancer Care aims to encourage comprehensive, multiprofessional cancer care across Europe and internationally. It publishes original research reports, literature reviews, guest editorials, letters to the Editor and special features on current issues affecting the care of cancer patients. The Editor welcomes contributions which result from team working or collaboration between different health and social care providers, service users, patient groups and the voluntary sector in the areas of: - Primary, secondary and tertiary care for cancer patients - Multidisciplinary and service-user involvement in cancer care - Rehabilitation, supportive, palliative and end of life care for cancer patients - Policy, service development and healthcare evaluation in cancer care - Psychosocial interventions for patients and family members - International perspectives on cancer care
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信